
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD30 CRISPR/Cas9 KO Plasmid (h) | sc-402068 | 20 µg | $397.00 | |||
CD30 HDR Plasmid (h) | sc-402068-HDR | 20 µg | $445.00 |
TNFRSF8 encodes CD30, a type I transmembrane receptor in the TNF receptor superfamily that is inducibly expressed on activated T and B lymphocytes and modulates immune activation states. CD30 signaling engages TRAF adaptors to regulate NF-κB and MAPK cascades, shaping transcriptional programs that control proliferation, differentiation, and apoptosis. Through cross-talk with cytokine signaling and antigen receptor pathways, CD30 contributes to immune homeostasis and inflammatory responses. Dysregulated CD30 expression and signaling are implicated in lymphoid malignancy biology and immune-mediated disease mechanisms, making TNFRSF8 a useful node for studying receptor-driven transcriptional rewiring.
CD30 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TNFRSF8 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the TNFRSF8 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, CD30 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined TNFRSF8 target site.
When co-transfected with CD30 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the TNFRSF8 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.